Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study...

Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)

Lonial, Sagar, Dimopoulos, Meletios, Weisel, Katja, White, Darrell, Moreau, Philippe, Mateos, Maria-Victoria, San Miguel, Jesus, Anderson, Kenneth, Shpilberg, Ofer, Grosicki, Sebastian, Spicka, Ivan,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
18
Language:
english
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2018.07.155
Date:
September, 2018
File:
PDF, 66 KB
english, 2018
Conversion to is in progress
Conversion to is failed